Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Cardiotoxicity × Spironolactone × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Polycystic Ovary Syndrome 8 Hyperandrogenism 4 Neoplasms 3 Triple Negative Breast Neoplasms 1 Skin Diseases 1 Rare Diseases 1 Obesity 1 Neoplasm Metastasis 1 Metabolic Syndrome 1 Leukemia, Myeloid, Acute 1 Inflammation 1 Heart Failure 1 Glioblastoma 1 Endocrine System Diseases 1 Critical Illness 1 Cardiovascular Diseases 1 Cardiotoxicity 1 Advanced Malignant Neoplasm 1 Acute Kidney Injury 1 Acanthosis Nigricans 1

Interventions

Doxorubicin 13 Exercise 8 Dexrazoxane 7 Cyclophosphamide 7 Razoxane 5 Carvedilol 5 Vincristine 4 Filgrastim 4 Radiotherapy 3 Methotrexate 3 Granulocyte Colony-Stimulating Factor 3 Etoposide 3 Echocardiography 3 Docetaxel 3 Atorvastatin 3 salicylhydroxamic acid 2 sacubitril and valsartan sodium hydrate drug combination 2 empagliflozin 2 Trastuzumab 2 Tablets 2 Prednisone 2 Leucovorin 2 Ivabradine 2 High-Intensity Interval Training 2 Cisplatin 2 Chemotherapy, Adjuvant 2 Bleomycin 2 Bisoprolol 2 sulforaphane 1 schizandrin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06005259 2023-08-22

SPIROTOX

University of Sao Paulo

Phase 4 Unknown

Heart Failure, Neoplasms, Cardiotoxicity

Data powered by HemOnc (CC BY 4.0) Colophon ⚡